PE20240372A1 - Anticuerpos y composiciones anti-nkg2a - Google Patents

Anticuerpos y composiciones anti-nkg2a

Info

Publication number
PE20240372A1
PE20240372A1 PE2023003150A PE2023003150A PE20240372A1 PE 20240372 A1 PE20240372 A1 PE 20240372A1 PE 2023003150 A PE2023003150 A PE 2023003150A PE 2023003150 A PE2023003150 A PE 2023003150A PE 20240372 A1 PE20240372 A1 PE 20240372A1
Authority
PE
Peru
Prior art keywords
compositions
nkg2a antibodies
nkg2a
antibodies
cancer
Prior art date
Application number
PE2023003150A
Other languages
English (en)
Inventor
Randi Westh Hansen
Franziska Katharina Uhlenbrock
Nikolaj Dietrich
Anne Worsaae
Michael Monrad Grandal
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20240372A1 publication Critical patent/PE20240372A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invencion se refiere a anticuerpos anti-NKG2A y a metodos para usarlos para aumentar la inmunidad en un paciente que lo necesita y en el tratamiento del cancer
PE2023003150A 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a PE20240372A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (1)

Publication Number Publication Date
PE20240372A1 true PE20240372A1 (es) 2024-03-05

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003150A PE20240372A1 (es) 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a

Country Status (14)

Country Link
US (1) US20220389100A1 (es)
EP (1) EP4347651A1 (es)
JP (1) JP2024520577A (es)
KR (1) KR20240016991A (es)
CN (1) CN117460748A (es)
AR (1) AR126001A1 (es)
AU (1) AU2022286617A1 (es)
BR (1) BR112023024772A2 (es)
CA (1) CA3222040A1 (es)
CO (1) CO2023015982A2 (es)
IL (1) IL308695A (es)
PE (1) PE20240372A1 (es)
TW (1) TW202313683A (es)
WO (1) WO2022253805A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
MX2010007935A (es) * 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
WO2016041947A1 (en) * 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
SG11201701388UA (en) * 2014-10-23 2017-03-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017046774A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
AU2017251250B2 (en) * 2016-04-12 2024-03-21 Les Laboratoires Servier Anti-TIM-3 antibodies and compositions
EP3878869A4 (en) * 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODY, METHOD FOR PREPARATION AND USE
CN113316590A (zh) * 2018-11-16 2021-08-27 百时美施贵宝公司 抗nkg2a抗体及其用途

Also Published As

Publication number Publication date
CO2023015982A2 (es) 2024-01-15
AR126001A1 (es) 2023-08-30
WO2022253805A1 (en) 2022-12-08
JP2024520577A (ja) 2024-05-24
IL308695A (en) 2024-01-01
CA3222040A1 (en) 2022-12-08
EP4347651A1 (en) 2024-04-10
AU2022286617A1 (en) 2023-12-21
CN117460748A (zh) 2024-01-26
TW202313683A (zh) 2023-04-01
KR20240016991A (ko) 2024-02-06
BR112023024772A2 (pt) 2024-02-15
US20220389100A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
PE20180268A1 (es) Composiciones que comprenden cepas bacterianas
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
CO2019007686A2 (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2020000508A1 (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.